| Entries |
| Document | Title | Date |
|---|
| 20080199885 | Overexpression of mammaglobin B in ovarian and endometrial tumors - a new diagnostic and therapeutic marker - The invention involves the discovery that the mammaglobin B gene is the single most overexpressed gene in primary ovarian serous papillary cancer over normal ovarian epithelium among over 14,000 genes tested. It is expressed over 800-fold higher in primary ovarian tumors than normal ovarian epithelium. Mammaglobin B gene expression was detected in endometrioid, mucinous, undifferentiated, serous papillary, clear cell, and mixed histology ovarian tumors. The protein can be found in blood and ascites fluid, and a simple blood test for the presence of mammaglobin B protein can provide early detection of ovarian and other cancers. The invention provides a method of screening for cancer involving detecting mammaglobin B in a fluid sample. | 08-21-2008 |
| 20080199886 | IGF BINDING PROTEINS - IGFBP-3 fusion proteins are provided that are useful, for example, in cell-based assays, as IGF antagonists, and in mapping IGF-I and IGF-II binding sites on other molecules such as wild-type IGFBP-3 and IGF agonist peptides identified by phage display. Methods for making such fusion proteins are also provided. | 08-21-2008 |
| 20080213802 | Diagnosis of Neurodegenerative Diseases - The invention relates to a method of diagnosis of vCJD in a diagnostic sample of a valid body tissue taken from a human subject, which comprises detecting an increased concentration of a protein in the diagnostic sample, compared with a sample of a control human subject, the protein being: beta-actin (SwissProt Ace. No. P60709), apolipoprotein A-IV precursor (SwissProt Acc. No. P06727); haptoglobin beta-chain consisting of residues 162-406 (SwissProt Acc. No. P00738); haemoglobin beta chain (SwissProt Ace. No. P02023); or alpha-1-antitrypsin (SwissProt Ace. No. P01009); or a decreased concentration of a protein in the diagnostic sample, compared with a sample of a control, normal human subject, the protein being plasma protease (C1) inhibitor precursor (SwissProt Acc. No. P05155); complement component 1, s sub-component (SwissProt Acc. No. P09871); butyrylcholinesterase precursor (SwissProt Acc. No. P06276); complement component C4B (SwissProt Acc. No. P01028); lumican (SwissProt Ace. No. P51884); alpha-fibrinogen precursor (SwissProt Ace. No. P02671); IGHG4 protein (Swiss Prot Ace. No. Q8TC63) or immunoglobulin lambda heavy chain. Other marker proteins are also disclosed. | 09-04-2008 |
| 20080220447 | Method for the Detection of Disease-Related Prion - Methods for the detection of the disease associated conformation of the prion protein as an indication of transmissible spongiform encephalopathies (TSEs), including preclinical detection of infected live animals and humans, and post-mortem detection methods are disclosed. In one aspect, the tissue or body fluid sample of a test subject is contacted with an antibody that binds only the disease related conformation of the prion protein under non-denaturing conditions. | 09-11-2008 |
| 20080227117 | Peptides as Biomarkers of Copd - The present invention relates to the identification of biomarkers for the disease condition COPD. The uses of such biomarkers in diagnosis and therapy and a novel method for their identification is are also described. | 09-18-2008 |
| 20080233597 | Method of Detecting or Differentiating Rheumatoid Arthritis and Method of Determining Stage of Disease or Degree of Dysfunction with Regard to Rheumatoid Arthritis - A method of readily detecting or differentiating rheumatoid arthritis, which has so far been diagnosed in a comprehensive manner based on various tests and clinical symptoms, and a method of readily and objectively estimating the stage of disease and the degree of dysfunction with regard to rheumatoid arthritis are provided. | 09-25-2008 |
| 20080241861 | Biological materials and methods useful in the diagnosis and treatment of diseases - The present invention relates to a method of making a β-form of a prion protein which preferably has more β-sheet than α-helix structure and is soluble in the absence of a denaturant and/or is non-aggregated and exhibits partial resistance to digestion with proteinase K. The invention also relates to use of the β-form in medicine, especially for raising antibodies useful in the treatment and/or diagnosis of prion diseases. The invention also relates to methods of screening for compounds which are capable of inhibiting and/or reversing the conversion of the native α-form of a prion protein to a β-form, and to uses of identified compounds in medicine. | 10-02-2008 |
| 20080248493 | ACRIDINIUM PHENYL ESTERS USEFUL IN THE ANALYSIS OF BIOLOGICAL SAMPLES - The present invention relates to methods and kits for detecting an analyte in a test sample using acridinium-9-carboxylate aryl esters. | 10-09-2008 |
| 20080254486 | Prion Sensors for Diagnosis of Transmissible Spongiform Encephalopathy or for Detection of Prions, and Use Thereof - Disclosed are prion sensors that may be used as a diagnostic tool to diagnose TSE, or to detect PrP | 10-16-2008 |
| 20080261241 | Targeted ubiquitination of proteins and screening methods using a new class of ubiquitin ligase proteins - Members of the IpaH superfamily constitute a novel class of E3 ubiquitin ligases which are useful for engineering products which modulate trafficking and destruction of target proteins inside a cell and useful targets for identifying new antimicrobial molecules which modulate, especially inhibit, E3 ligases. | 10-23-2008 |
| 20080274479 | Assay of Ubiquitinization of Synoviolin and Use Thereof in Screening - The present invention relates to an assay method for determining a auto-ubiquitination activity of synoviolin, comprising reacting synoviolin and ubiquitin in a reaction system containing them and determining an amount of ubiquitin binding to synoviolin, to a method of screening a substance capable of regulating such an activity, and to a kit for auto-ubiquitination assay of synoviolin. | 11-06-2008 |
| 20080286808 | Methods for production of unstructured recombinant polymers and uses thereof - The present invention provides unstructured recombinant polymers (URPs) and proteins containing one or more of the URPs. The present invention also provides microproteins, toxins and other related proteinaceous entities, as well as genetic packages displaying these entities. The present invention also provides recombinant polypeptides including vectors encoding the subject proteinaceous entities, as well as host cells comprising the vectors. The subject compositions have a variety of utilities including a range of pharmaceutical applications. | 11-20-2008 |
| 20080286809 | Methods - A method for identifying a compound expected to be useful in modulating a WNK (With No Lysine Kinase) isoform protein kinase activity, the method comprising the steps of (1) determining whether a test compound modulates the protein kinase activity of a WNK isoform polypeptide on the substrate SPAK (STE20/SPS1-related Proline-Alanine-rich Kinase) or OSR1 (Oxidative Stress Response kinase-1) and (2) selecting a compound which modulates the said WNK isoform polypeptide protein kinase activity. Such a compound may be useful as an antihypertensive agent or for the treatment of, for example, Gordon's syndrome. | 11-20-2008 |
| 20080286810 | Use of Inhibtors of Glutaminyl Cyclases for Treatment and Prevention of Disease - Novel physiological substrates of mammalian glutaminyl cyclase (QC, EC 2.3.2.5), new effectors of QC, methods for screening for such effectors, and the use of such effectors and pharmaceutical compositions comprising such effectors for the treatment of conditions that can be treated by modulation of QC-activity. Preferred compositions additionally comprise inhibitors of DP IV or DP IV-like enzymes for the treatment or alleviation of conditions that can be treated by modulation of QC- and DP IV-activity. | 11-20-2008 |
| 20080305496 | Method for identifying a compound that modulates SIR2 protein activity - The present invention relates to a method for identifying compounds that modulate the activity of sirtuin deacetylase protein family members. Compounds of the invention are identified by designing or screening for a compound which binds to at least one amino acid residue of the newly identified nicotinamide inhibition and base exchange site of Sir2 and testing the compound for its ability to modulate the activity of the Sir2 protein. Compositions and methods for preventing or treating diseases or disorders associated with Sir2 are also provided. | 12-11-2008 |
| 20090011433 | RECOMBINANT BIOTIN CARBOXYLASE DOMAINS FOR IDENTIFICATION OF ACETYL CoA CARBOXYLASE INHIBITORS - A peptide comprising an Acetyl CoA carboxylase (ACCase) having a deleted biotin binding domain, having a deleted carboxy transferase domain, and having a functional biotin carboxylase (BC) domain is described. A nucleic acid that encodes the peptide described above and a recombinant host cell that contains the nucleic acid and expresses the encoded peptide is also described. A method of identifying Acetyl CoA carboxylase inhibitors, fungicides, herbicides and pharmaceuticals is also described herein. | 01-08-2009 |
| 20090017468 | METHOD OF SCREENING COMPOUND DIRECTLY ACTIVATING GLYCOGEN SYNTHASE - The present invention provides a therapeutic agent for diabetes comprising a compound directly activating glycogen synthase as an active ingredient. The present invention further provides a method for screening compounds directly activating glycogen synthase. | 01-15-2009 |
| 20090029390 | METHOD FOR QUANTITATIVE ANALYSIS OF INTERACTIONS BETWEEN HIF-1ALPHA C-TERMINAL PEPTIDES AND CBP OR p300 PROTEINS AND METHOD OF SCREENING INHIBITORS USING THE SAME - The present invention relates to a method for quantitative analysis of interactions between fluorescein-labeled HIF-1α (alpha) C-terminal peptides and cAMP-responsive element binding protein (CBP) or p300 proteins, and a method of screening inhibitors against the formation of HIF-1α-p300 or HIF-1α-CBP protein complexes using the above method. | 01-29-2009 |
| 20090029391 | REAGENTS AND METHODS FOR THE DETERMINATION OF PK/ADME-TOX CHARACTERISTICS OF NEW CHEMICAL ENTITIES AND OF DRUG CANDIDATES - Methods using colloidal conductive polymers, noble metal nanoparticles or of stable metal/conductive polymer composite colloids as reagents for at least the in vitro prediction of, if not the determination of, PK/ADME-tox properties of new chemical entities (NCEs) are provided. Also provided are kits that include the subject methods and reagents for application thereof. The salient characteristics of these methods and reagents pertaining to the present invention reside in the fact that the reactions in which they are involved are homogeneous, rapid, and proceed as “mix and read” processes. | 01-29-2009 |
| 20090029392 | MAGNETIC-NANOPARTICLE CONJUGATES AND METHODS OF USE - The present invention provides novel compositions of binding moiety-nanoparticle conjugates, aggregates of these conjugates, and novel methods of using these conjugates, and aggregates. The nanoparticles in these conjugates can be magnetic metal oxides, either monodisperse or polydisperse. Binding moieties can be, e.g., oligonucleotides, polypeptides, or polysaccharides. Oligonucleotide sequences are linked to either non-polymer surface functionalized metal oxides or with functionalized polymers associated with the metal oxides. The novel compositions can be used in assays for detecting target molecules, such as nucleic acids and proteins, in vitro or as magnetic resonance (MR) contrast agents to detect target molecules in living organisms. | 01-29-2009 |
| 20090042217 | Methods and Kits for Determining Blood Coagulation - A method of determining a coagulation status of a blood sample is provided. The method comprising determining an expression and/or activity ratio of Tissue Factor (TF) to Tissue Factor Pathway Inhibitor (TFPI) in cellular microparticles of the blood sample, wherein the ratio is indicative of the coagulation status of the blood sample. | 02-12-2009 |
| 20090047688 | REAGENTS, KITS AND METHODS FOR DETECTING BIOLOGICAL MOLECULES BY ENERGY TRANSFER FROM AN ACTIVATED CHEMILUMINESCENT SUBSTRATE TO AN ENERGY ACCEPTOR DYE - Reagents, kits and methods for detecting biological molecules by energy transfer from an activated chemiluminescent substrate to an energy acceptor dye such as a J-aggregated dye are described. | 02-19-2009 |
| 20090053739 | Ligand for G-protein coupled receptor FPRL2 and uses thereof - The present invention relates to methods, reagents and kits for detecting of formyl peptide receptor like-2 (FPRL2) polypeptide activity in a sample and identifying agents which modulate polypeptide activity. It further relates to antibodies raised against FPRL2. It further relates to substances for preventing, treating and/or alleviating diseases or disorders characterized by dysregulation of FPRL2 polypeptide signalling. | 02-26-2009 |
| 20090061459 | Reagents for the detection of protein phosphorylation in carcinoma signaling pathways - The invention discloses nearly 443 novel phosphorylation sites identified in signal transduction proteins and pathways underlying human carcinoma, and provides phosphorylation-site specific antibodies and heavy-isotope labeled peptides (AQUA peptides) for the selective detection and quantification of these phosphorylated sites/proteins, as well as methods of using the reagents for such purpose. Among the phosphorylation sites identified are sites occurring in the following protein types: Protein kinases (including Serine/Threonine dual specificity, and Tyrosine kinases), Adaptor/Scaffold proteins, Transcription factors, Phospoatases, Tumor supressors, Ubiquitin conjugating system proteins, Translation initiation complex proteins, RNA binding proteins, Apoptosis proteins, Adhesion proteins, G protein regulators/GTPase activating protein/Guanine nucleotide exchange factor proteins, and DNA binding/replication/repair proteins, as well as other protein types. | 03-05-2009 |
| 20090081705 | NOVEL PEPTIDES AND COMPOSITIONS WHICH MODULATE APOPTOSIS - The present invention is directed to novel peptides and compositions capable of modulating apoptosis in cells, and to methods of modulating apoptosis employing the novel peptides and compositions of the invention. In one aspect, the invention is directed to a novel peptide designated the “GD domain,” which is essential both to Bak's interaction with Bcl-x | 03-26-2009 |
| 20090081706 | CRYSTALLINE FORM OF THE CATALYTIC DOMAIN OF AURORA 2 KINASE AND METHODS OF USE THEREOF - The present invention discloses nucleic acids that encode an active human Aurora 2 kinase catalytic domain. The present invention also discloses methods of growing X-ray diffractable crystals of polypeptides comprising the active human Aurora 2 kinase catalytic domain. The present invention further discloses a crystalline form of a catalytic domain of human Aurora 2 kinase. In addition, the present invention discloses methods of using the X-ray diffractable crystals of human Aurora 2 kinase in structure assisted drug design to identify compounds that can modulate the enzymatic activity of human Aurora 2 kinase. | 03-26-2009 |
| 20090104629 | USE OF BIOMARKERS OF ALZHEIMER'S DISEASE FOR DIAGNOSTIC TESTS AND DRUG SCREENING - The invention relates to method of diagnosing Alzheimer's disease or detecting a predisposition to Alzheimer's disease including providing a test cell sample from a subject, exposing the test cell sample to labeled amyloid beta peptides, and determining the level of labeled amyloid beta peptides in the test cell sample, wherein lower levels of labeled amyloid beta peptides in the test cell sample compared to a control cell sample are indicative of Alzheimer's disease. | 04-23-2009 |
| 20090148867 | UNIVERSAL FLUORESCENT SENSORS - A probe comprises: (1) a target binding site moiety which is attached to a first fluorescent polypeptide; (ii) a mimic moiety which is capable of binding to the target binding site moiety and is attached to a second fluorescent polypeptide; and (iii) a linker which connects the two fluorescent polypeptides and which allows the distance between said fluorescent polypeptides to vary, said fluorescent polypeptides being so as to display fluorescence resonance energy transfer (FRET) between them, wherein the linker comprises one or more of: (1) a sequence capable of being recognised and bound by an immobilized component; (2) a protease cleavage site; (3) a non-analyte binding site; (4) two or more copies of the sequence (SerGly | 06-11-2009 |
| 20090155815 | CRYSTAL STRUCTURE OF THE CARBOXYL TRANSFERASE DOMAIN OF HUMAN ACETYL-COA CARBOXYLASE 2 PROTEIN (ACC2 CT) AND USES THEREOF - A crystallized human ACC2 CT protein as well as a description of the X-ray diffraction pattern of the crystal are disclosed. The diffraction pattern allows the three dimensional structure of human ACC2 CT to be determined at atomic resolution so that ligand binding sites on human ACC2 CT can be identified and the interactions of ligands with human ACC2 CT amino acid residues can be modeled. Models prepared using such maps permit the design of ligands which can function as active agents which include, but are not limited to, those that function as inhibitors of human ACC2 and human ACC1 proteins. | 06-18-2009 |
| 20090155816 | BIOSENSOR HAVING NANO WIRE FOR DETECTING FOOD ADDITIVE MONO SODIUM GLUTAMATE AND MANUFACTURING METHOD THEREOF - There is provided a biosensor capable of increasing a detecting sensitivity of a target substance of glutamate, by using a nano wire having excellent electrical characteristics and by immobilizing a receptor of glutamate to be detected on a substrate which is disposed between a nano wire and another nano wire and a method for manufacturing the same. The biosensor for detecting glutamate according to the present invention can be manufactured with an arrangement in which the nano wire is selectively arranged on a solid substrate in a matrix. Since this biosensor can prevent the degradation of the nano wire in the electrical characteristic, it can sensitively detect glutamate even through a small amount thereof is contained in a food so that it can be effectively used in detecting the food additive existing in the processed foodstuffs. | 06-18-2009 |
| 20090170127 | Screening Compounds for Activity in Modulating Chloride Ion Transport - A method for screening a test compound for activity in modulating the activity of the chloride channel ClC-7 either directly or by modulating the subcellular localization of Ostm1 comprises determining whether test compound inhibits the binding of Ostm1 to ClC-7. Compounds active in the screen are candidates for use in treating bone resorption conditions such as Osteoporosis by modulating the activity of osteoclasts. | 07-02-2009 |
| 20090170128 | Crystallization and Structure Determination of BACE and/or BACE-Like Proteins - The x-ray crystal structure of human BACE or BACE-like proteins is useful for solving the structure of other molecules or molecular complexes, and identifying and/or designing potential modifiers of human BACE activity. | 07-02-2009 |
| 20090203045 | Crystal Structure Of Soluble Glutaminyl Cyclase - A crystalline structure of glutaminyl cyclase (QC) is described. Also described are the methods of preparing the crystalline structure of QC and the methods for identifying candidate inhibitors of QC. In addition, a structural basis for the rational design or identification of new inhibitors that may be used to treat QC-associated disorders is also described. | 08-13-2009 |
| 20090215081 | SCREENING METHOD FOR ANTICANCER DRUG - The screening method for an anticancer drug comprises selecting a compound which blocks the kinase activity of TNIK, or blocks the combination of TNIK with β-catenin/TC4 transcription complex. | 08-27-2009 |
| 20090220991 | Reagents for the detection of protein phosphorylation in leukemia signaling pathways - The invention discloses nearly 480 novel phosphorylation sites identified in signal transduction proteins and pathways underlying human Leukemia, and provides phosphorylation site specific antibodies and heavy-isotope labeled peptides (AQUA peptides) for the selective detection and quantification of these phosphorylated sites/proteins, as well as methods of using the reagents for such purpose. Among the phosphorylation sites identified are sites occurring in the following protein types: adaptor/scaffold proteins, acetyltransferases, actin binding proteins, adhesion proteins, apoptosis proteins, calcium-binding proteins, cell cycle regulation proteins, cell surface proteins, channel proteins, chaperone proteins, contractile proteins, cytokine proteins, cytoskeletal proteins, G protein regulators and GTPase activating proteins, guanine nucleotide exchange factors, helicase proteins, immunoglobulin superfamily proteins, inhibitor proteins, protein kinases, lipid kinases, ligases, lipid binding proteins, methytransferases, motor proteins, oxidoreductases, phosphotases, phosphodiesterases, phospholipases, proteases, receptor proteins, trascription factors, transferases, translation/transporter proteins, and ubiquitin conjugating system proteins. | 09-03-2009 |
| 20090220992 | METHODS FOR THE IDENTIFICATION OF LRRK2 INTERACTING MOLECULES AND FOR THE PURIFICATION OF LRRK2 - The invention provides in a first aspect a method for the identification of an LRRK2 interacting compound, comprising the steps of providing a protein preparation containing LRRK2, contacting the protein preparation with indol ligand 91 immobilized on a solid support under conditions allowing the formation of an indol ligand 91-LRRK2 complex, incubating the indol ligand 91-LRRK2 complex with a given compound, and determining whether the compound is able to separate LRRK2 from the immobilized indol ligand 91. Furthermore, the invention relates to a method for the identification of an LRRK2 interacting compound, comprising the steps of providing a protein preparation containing LRRK2, contacting the protein preparation with indol ligand 91 immobilized on a solid support and with a given compound under conditions allowing the formation of an indol ligand 91-LRRK2 complex, and detecting the indol ligand 91-LRRK2 complex. Additionally, the invention provides a method for the identification of an LRRK2 interacting compound, comprising the steps of providing two aliquots of a protein preparation containing LRRK2, contacting one aliquot with indol ligand 91 immobilized on a solid support under conditions allowing the formation of an indol ligand 91-LRRK2 complex, contacting the other aliquot with indol ligand 91 immobilized on a solid support and with a given compound under conditions allowing the formation of an indol ligand 91-LRRK2 complex, and determining the amount of indol ligand 91-LRRK2 complex. Furthermore, the invention relates to a method for the purification of LRRK2, comprising the steps of providing a protein preparation containing LRRK2, contacting the protein preparation with indol ligand 91 immobilized on a solid support under conditions allowing the formation of an indol ligand 91-LRRK2 complex, and separating LRRK2 from the immobilized indol ligand 91. | 09-03-2009 |
| 20090239243 | Method of identifying compounds useful to treat neuronal degenerative diseases - Methods of identifying agents that inhibit ROS by altering the binding of a GTPase such as Rac to SOD, agents identified by the method, and methods of using compounds that inhibit ROS to inhibit or treat neuronal degenerative diseases, are provided. | 09-24-2009 |
| 20090239244 | MODULATORS OF PROTEIN PHOSPHATASE 2A AND PP2A METHYL ESTERASE - The disclosure relates to modulation of protein phosphorylation, including information derived from the structures and activities of the proteins designated protein phosphatase 2A (PP2A) and PP2A methyl esterase. The disclosure contained herein provides compounds and methods for identification of compounds that antagonize the function of PME, and thus reduce levels of PP2A demethylation activity. Over-expression or gain-of-function of PME contributes to a range of diseases such as cancer, thus inhibition of PME by antagonists may provide a strategy for therapeutic intervention. | 09-24-2009 |
| 20090246803 | NAD BIOSYNTHESIS SYSTEMS - The present invention generally relates to a nicotinamide adenine dinucleotide (NAD) biosynthesis system and methods of screening for NAD biosynthesis effectors. Among the various aspects of the present invention is the provision of an in vitro-reconstituted mammalian NAD biosynthesis system that can be used for the high-throughput screening of chemical activators and inhibitors for mammalian NAD biosynthesis. Another aspect of the invention provides a method of identifying a compound that effects in vivo activity of NAD metabolic enzymes. Further aspects of the invention include nucleic acid sequences, vectors, and transformed cells that can be used in the methods described herein. | 10-01-2009 |
| 20090253150 | Three Part Assay for Kinase or Phosphatase Activity - The present invention relates to a method of determining kinase or phosphatase activity based on a three parts system. The method comprises contacting a binding partner which can bind phosphorylated peptides, a detection molecule and a substrate peptide. Determination of activities is achieved by measuring energy transfer between an energy donor and an energy acceptor that are present on the detection molecule and the substrate molecule. | 10-08-2009 |
| 20090263831 | UBIQUITIN LIGASE ASSAY - The invention relates to assays for measuring ubiquitin ligase activity and for identifying modulators of ubiquitin ligase enzymes. | 10-22-2009 |
| 20090263832 | Reagents for the Detection of Protein Phosphorylation in Leukemia Signaling Pathways - The invention discloses nearly 123 novel phosphorylation sites identified in signal transduction proteins and pathways underlying human Leukemia, and provides phosphorylation-site specific antibodies and heavy-isotope labeled peptides (AQUA peptides) for the selective detection and quantification of these phosphorylated sites/proteins, as well as methods of using the reagents for such purpose. Among the phosphorylation sites identified are sites occurring in the following protein types: protein kinases, adaptor/scaffold proteins, phosphatase/phospholipases, G proteins/GTPase activating proteins/guanine nucleotide exchange factors, cellular metabolism enzymes, DNA binding proteins, cytoskeletal proteins, cell cycle regulation proteins, proteases, RNA binding proteins, transcription proteins, translation initiation complex proteins, transferases, ubiquitin conjugating system proteins, vesicle proteins, actin binding proteins, apoptosis proteins, chemokine proteins, enzyme proteins extra cellular matrix proteins, helicases, hydrolases, immunoglobin superfamily proteins, inhibitor proteins, isomerases, ligases, lipid binding proteins, methyltransferases, motor proteins, receptor proteins, and chaperone proteins. | 10-22-2009 |
| 20090263833 | In vitro estimation of in vivo half-life binding proteins - The present invention discloses methods used to estimate the in vivo half-life of a binding protein of interest. The disclosed methods involve (a) determining for a binding protein of interest and for each of at least two different reference binding proteins an in vitro half-life using an in vitro protease reaction assay, wherein said reference binding proteins have known different in vivo half-lives, (b) determining the correlation between the known in vivo half-lives and the in vitro proteolytic half-lives of each of the reference binding proteins, and (c) estimating from said correlation between the known in vivo half-lives and the in vitro proteolytic half-lives of the reference binding proteins the in vivo half-life of the binding protein of interest that correlates with the in vitro proteolytic half-life of the binding protein of interest. | 10-22-2009 |
| 20090269785 | CRYSTAL STRUCTURE OF MONOACYLGLYCEROL LIPASE (MGLL) - A number of soluble engineered forms of MGLL that are suitable for high-throughput screening and protein crystallization, as well as a crystallized form of monoacylglycerol lipase protein (MGLL) and descriptions of the X-ray diffraction patterns are disclosed. The engineered constructs of MGLL permit the expression and purification of protein suitable for crystallography or high-throughput screening and identification of ligands, which can function as active agents to MGLL. The X-ray diffraction patterns allow the three dimensional structure of MGLL to be determined at atomic resolution so that ligand binding sites on MGLL can be identified and the interactions of ligands with MGLL amino acid residues can be modeled. Models prepared using such maps permit the design of ligands which can function as active agents which include, but are not limited to, those that function as inhibitors of MGLL. | 10-29-2009 |
| 20090275054 | Pancreatic Cancer Genes - The present invention provides the art with the DNA coding sequences of polynucleotides that are up-or-down-regulated in cancer and dysplasia. These polynucleotides and encoded proteins or polypeptides can be used in the diagnosis or identification of cancer and dysplasia. Inhibitors of the up-regulated polynucleotides and proteins can decrease the abnormality of cancer and dysplasia. Enhancing the expression of down-regulated polynucleotides or introducing down-regulated proteins to cells can decrease the growth and/or abnormal characteristics of cancer and dysplasia. | 11-05-2009 |
| 20090298093 | Reagents for the Detection of Protein Phosphorylation in ATM & ATR Kinase Signaling Pathways - The invention discloses nearly 300 novel phosphorylation sites identified in signal transduction proteins and pathways underlying human ATM/ATR kinase signaling pathways, and provides phosphorylation-site specific antibodies and heavy-isotope labeled peptides (AQUA peptides) for the selective detection, profiling and quantification of these phosphorylated sites/proteins, as well as methods of using the reagents for such purpose. Among the phosphorylation sites identified are sites occurring in the following protein types: DNA repair proteins, Adaptor/Scaffold proteins, Cell cycle regulation proteins, G Protein/GTPase Activating/Guanine Nucleotide Exchange Factor proteins, DNA binding proteins, DNA replication proteins, Kinases, Disease associated proteins proteins, Methyltransferase, Ubiquitin conjugating proteins, Proteases, Phosphatases, and Transcription proteins. | 12-03-2009 |
| 20090305306 | Lectin Complement Pathway Assays and Related Compositions and Methods - This invention is related, in part, to assays for analyzing the lectin complement pathway (LCP) as well as to compositions and methods related thereto. | 12-10-2009 |
| 20100003701 | COVALENT MODIFICATION AND CONJUGATION OF LUCIFERASE - A process for reversible chemical modification of the luciferase, a process for the covalent conjugation of a reversibly modified luciferase to a chemical moiety (a protein or a binding partner such as biotin or an antibody), a process for reactivation of the reversibly-modified and inactivated luciferase, a process for making the said luciferase conjugates and a bioluminescent assay method that uses covalently conjugated firefly luciferase are taught. The present invention also relates to a composition comprising a reversibly modified luciferase, as well as a composition comprising a reversibly modified luciferase covalently conjugated to a chemical moiety. | 01-07-2010 |
| 20100021940 | Method for Determining the Activity of a Protease in a Sample - There is provided a method for determining the activity of a protease in a sample. The method comprises (i) admixing said sample with a substrate, wherein the substrate has the formula (1a) wherein: R | 01-28-2010 |
| 20100021941 | METHODS OF IDENTIFYING MODULATORS OF UBIQUITIN LIGASES - Methods for identifying ubiquitin ligases and ubiquitin ligase modulators are disclosed. The methods comprise combining the components of a ubiquitylation reaction and using proteins that contain motifs that recognize ubiquitylated sites in the detection of ubiquitylation. | 01-28-2010 |
| 20100028909 | In Vitro Method for Diagnosing and Monitoring Metastasized Bladder Cancer Using the Determination of MMP-7 in the Circulation of Patients - The present invention relates to the use in diagnostic in vitro methods for the detection, early detection, monitoring and/or prognosis of metastatic bladder cancer in human patients of matrix metalloproteinase 7 (MMP-7) and/or its precursors and fragments with MMP-7 immunoreactivity that can be measured in blood, serum or plasma samples from the patient. | 02-04-2010 |
| 20100041070 | Immunoassay and method of use - A method for performing an immunoassay is described. The method is particularly useful for detecting extracellular polysaccharide (EPS) and/or lipopolysaccharide (LPS) producing microorganisms. The method is particularly useful for detecting microorganisms which produce extracellular polysaccharides (EPS) also known as exocellular polysaccharides, capsule, and/or lipopolysaccharides (LPS). In a preferred method for detecting microorganisms which produce EPS, LPS, or both, the EPS and/or LPS is extracted from a sample with cetyltrimethylammonium bromide (CTAB) to produce molecular aggregates which are then preferentially bound to colored polystyrene latex particles over other components in the sample, and the bound EPS and/or LPS detected using a lateral flow immunoassay apparatus which has immobilized thereon antibodies specific for the EPS and/or LPS. The method can also be used to detect particular viruses, for example viruses of the potyviridae or tobamoviridae group. | 02-18-2010 |
| 20100068730 | METHOD FOR SCREENING ANTI-CANCER COMPOUNDS INHIBITING FUNCTION OF TM4SF5 AND ANTI-CANCER COMPOSITION CONTAINING CHALCONE COMPOUNDS - The present invention relates to a method for screening an anticancer compound and an anticancer compound screened using the method, and more particularly, to a method for screening an anticancer compound, the method comprising: culturing cancer cells expressing the oncogenic protein transmembrane 4 L6 family member 5 (TM4SF5), expressed as the polypeptide of SEQ ID NO: 2, treating the cancer cells with an anticancer candidate, and determining that the anticancer candidate is an anticancer substance when the candidate exhibits antagonistic activity against tumor formation and metastasis based on several events through the molecular mechanism of TM4SF5. The present invention also relates to chalcone compounds screened to have anticancer activity using the method, and an anticancer composition comprising the compound as an effective ingredient. | 03-18-2010 |
| 20100105078 | Compositions And Methods Of A Phosphatidic Acid Binding Protein - TGD2 proteins of | 04-29-2010 |
| 20100136580 | DISHEVELED PDZ MODULATORS - The invention provides modulators of Dvl PDZ-ligand interaction, and methods of identifying and using these modulators. | 06-03-2010 |
| 20100143942 | METHOD OF DETECTION - A method of detection of an analyte in which (i) a protein comprising a moiety capable of binding the analyte and a fluorescent label is contacted with a medium suspected of containing the analyte; (ii) the analyte, if present, binds to the moiety; (iii) the protein is subjected to incident radiation to excite the protein and induce intrinsic emission therefrom; whereby the intrinsic emission from the protein is converted through Fluorescence Resonance Energy Transfer (FRET) into emission from the fluorescent label and the amount of said FRET is affected by the binding of the analyte to the moiety; and, (iv) the emission from the fluorescent label is measured; whereby the level of emission from the fluorescent label is indicative of the presence of the analyte, and wherein the protein undergoes no substantial conformational charge during the method. A kit for carrying out the method of the invention and a protein are also provided. | 06-10-2010 |
| 20100151495 | Reagents for the detection of protein phosphorylation in carcinoma signaling pathways - The invention discloses nearly 443 novel phosphorylation sites identified in signal transduction proteins and pathways underlying human carcinoma, and provides phosphorylation-site specific antibodies and heavy-isotope labeled peptides (AQUA peptides) for the selective detection and quantification of these phosphorylated sites/proteins, as well as methods of using the reagents for such purpose. Among the phosphorylation sites identified are sites occurring in the following protein types: Protein kinases (including Serine/Threonine dual specificity, and Tyrosine kinases), Adaptor/Scaffold proteins, Transcription factors, Phospoatases, Tumor supressors, Ubiquitin conjugating system proteins, Translation initiation complex proteins, RNA binding proteins, Apoptosis proteins, Adhesion proteins, G protein regulators/GTPase activating protein/Guanine nucleotide exchange factor proteins, and DNA binding/replication/repair proteins, as well as other protein types. | 06-17-2010 |
| 20100159482 | PROTEINASE K INHIBITORS, METHODS AND COMPOSITIONS THEREFOR - The synthesis, biological evaluation, and molecular modeling of alkoxysuccinyl-peptidyl-haloalkyl ketones for use as proteinase K inhibitors are described. Sample preparation processes for in situ RNA or DNA analysis using such inhibitors, methods and compositions therefor are provided. | 06-24-2010 |
| 20100190188 | MUTANT G-PROTEIN COUPLED RECEPTORS AND METHODS FOR SELECTING THEM - A method for selecting a G-protein coupled receptor (GPCR) with increased stability, the method comprising (a) providing one or more mutants of a parent GPCR, (b) selecting a ligand, the ligand being one which hinds to the parent GPCR when the GPCR is residing in a particular conformation, (c) determining whether the or each mutant GPCR has increased stability with respect to binding the selected ligand compared to the stability of the parent GPCR with respect to binding that ligand, and (d) selecting those mutants that have an increased stability compared to the parent GPCR with respect to binding the selected ligand. Mutants of β-adrenergic receptor, adenosine receptor and neurotensin receptor are also disclosed. | 07-29-2010 |
| 20100221750 | Methods and Compositions for Risk Stratification - The present invention provides an approach for the simultaneous determination of the activation states of a plurality of proteins in single cells. This approach permits the rapid detection of heterogeneity in a complex cell population based on activation states, and the identification of cellular subsets that exhibit correlated changes in activation within the cell population. Moreover, this approach allows the correlation of cellular activities or properties. In addition, the use of potentiators of cellular activation allows for characterization of such pathways and cell populations. | 09-02-2010 |
| 20100227336 | METHOD FOR THE MEASURE OF MOLECULAR INTERACTIONS BY MEASUREMENT OF THE LIGHT REFLECTED BY PLANAR SURFACES - Procedure for the quantitative determination of interactions of ligands with receptors adsorbed or immobilized on the surface of a solid material which can be functionalized, transparent and with low refractive index, by direct measure of the reflection of light. | 09-09-2010 |
| 20100248265 | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF CANCER - Provided herein are methods and compositions useful in the diagnosis and treatment of cancer. The methods and compositions typically involve detecting a level of phosphorylation of mTOR at serine 2481 in a subject and comparing the level of phosphorylation of mTOR at serine 2481 in said subject with a standard control. | 09-30-2010 |
| 20100255500 | IDENTIFICATION METHOD OF GLYCOPROTEINS USING A SPECIFIC LECTIN PRECIPITATION - The present invention relates to an analyzing method of measuring the changes of glycosylation in various glycoproteins which participate in tumorigenesis and metastasis. | 10-07-2010 |
| 20100273188 | Serum Prolactin Binding Protein in Epithelial Carcinoma - The present invention relates to antibodies that have specificity towards prolactin binding protein (PRLBP) that is either bound to a binding partner or unbound to a binding partner, as well as antibodies towards PRLBP regardless of the binding state of PRLBP. The present invention also provides methods of using these PRLBP-specific antibodies, such as method of diagnosing and monitoring the progression of diseases such as epithelial carcinomas, osteoporosis, infertility and cachexia. | 10-28-2010 |
| 20100279314 | COMPOSITION AND METHOD FOR MEASURING THALLIUM INFLUX AND EFFLUX - The present invention relates to methods for detecting the activity of an ion channel in a cell. The methods comprise providing a loading buffer solution to a cell that has an ion channel. The loading buffer comprises at least one thallium indicator (e.g., an environmentally sensitive, luminescent dye) and a physiological concentration of chloride ions. The methods further comprise providing a stimulus buffer to the cell, wherein the stimulus buffer comprises thallium (e.g., thallium ions). Providing the stimulus buffer causes thallium influx into the cell through the ion channel. After providing the stimulus buffer, the luminescence (e.g., fluorescence) of the dye in the cell is detected. The luminescence of the dye can change in the presence or absence of thallium. The methods may be used to measure influx or efflux of thallium through an ion channel. | 11-04-2010 |
| 20110008800 | CRYSTAL STRUCTURE OF CMY-10, A BETA-LACTAMASE CAUSING ANTIBIOTIC RESISTANCE WITH EXTENDED-SUBSTRATE SPECTRUM - The present invention related to a method for crystallizing a CMY-10 being a β-lactamase with extended-substrate spectrum, a crystal of CMY-10, and a crystal structure of CMY-10. With utilization of three-dimensional structure of CMY-10 protein provided by the present invention, it is possible to develop novel antibiotics or inhibitors that can prevent an emergence of resistance bacteria appeared by plasmatic class C β-lactamases having extended-substrate specificity. | 01-13-2011 |
| 20110033873 | PROTEINIC MARKER FOR EARLY DIAGNOSIS OF LIVER CANCER - The present invention relates to proteomic markers for early detection of hepatocellular carcinoma, compositions for detecting changes of these proteomic markers, kits for detection of hepatocellular carcinoma, methods for detecting proteomic markers including these compositions, methods for screening drugs for hepatocellular carcinoma using these proteomic markers, and antibodies specific for these proteomic markers. | 02-10-2011 |
| 20110045495 | COMPOSITION AND METHOD FOR DIAGNOSIS OR DETECTION OF RENAL CANCER - The present invention relates to a method for detection of a renal cancer, comprising measuring any one of or a plurality of polypeptides shown in SEQ ID NOS: 1-7, mutants thereof, or fragments thereof in a biological sample from a subject, and to a composition for diagnosis or detection of the renal cancer. | 02-24-2011 |
| 20110065128 | Methods for Assessing CDK5 Activation and Function - As described herein, signaling events occurring in neurons or at neuronal synapses have been identified that involve Cdk5 and various other molecules which bind to, are activated by, and/or activate Cdk5. Of particular relevance are interactions that stimulate calpain cleavage of p35 into p25, which binds Cdk5 in pathologic states. Assays to identify modulators of these interactions are provided. | 03-17-2011 |
| 20110070596 | AGENTS AND METHODS FOR ANALYZING PROTEIN INTERACTIONS - Agents and methods for qualitative and quantitative analysis a protein complex or protein complexes using isotope-labeled symmetrical bifunctional crosslinkers and mass spectrometry are provided. Targeting moieties, cell permeability moieties, or affinity moieties, may be appended to the bifunctional crosslinkers. The isotope-labeled symmetrical bifunctional crosslinkers may be used in a kit or as a library. | 03-24-2011 |
| 20110070597 | Thin-Film Passive Samplers for Detection of Hydrophobic Organic Contaminants and Estrogenicity in Various Environments - A thin-film passive sampler for use in detecting hydrophobic organic contaminants in air or aqueous environments. The sampler features a relatively thin layer of a suitable absorbent matrix coated directly on a solid support unit made of an inert material such as titanium or glass fibers. The passive samplers are simple and cost-effective to manufacture, easy to use, and exhibit rapid equilibration times and high accuracy. | 03-24-2011 |
| 20110091905 | BIOCHIP AND METHOD OF DETECTING REACTION FROM THE SAME - Provided are a biochip and a method of detecting a reaction from the biochip. This method includes preparing a first mixture solution of polyvinylpyrrolidone (PVP) and a sample including target molecules, measuring absorbance or transmittance of the first mixture solution, preparing a second mixture solution including the PVP, the sample, and a receptor of the target molecules, measuring absorbance or transmittance of the second mixture solution, and calculating an absorbance or transmittance difference between the first mixture solution and the second mixture solution. Thus, it is possible to reduce the production cost of the biochip by inducing a reaction of an antigen and an antibody using PVP. Further, it is possible to detect an accurate quantity of the antigen by analyzing a quantity of antigen on the basis of the absorbance or transmittance difference. | 04-21-2011 |
| 20110097739 | BLOOD-BRAIN BARRIER EPITOPES AND USES THEREOF - The invention features a method of identifying an agent and generating an antibody that can cross the blood brain barrier, through the use of novel antigen isoforms of transmembrane domain protein 30A (TMEM30A). This is useful in establishing mechanisms of transmigration across the blood-brain barrier. These antigens are enriched in brain endothelium compared to other endothelial cells and may have better selectivity and capacity for brain delivery compared to transferrin and insulin receptors. One antigen is TMEM30A. | 04-28-2011 |
| 20110104713 | PRODUCTS AND PROCESSES FOR MODULATING PEPTIDE-PEPTIDE BINDING DOMAIN INTERACTIONS - The present invention relates to therapeutic compounds and methods of use of these therapeutic compounds for treating cellular proliferative disorders. The invention also provides three-dimensional structures of a Polo-like kinase and methods for designing or selecting small molecule inhibitors using these structures, and the therapeutic use of such compounds. The invention also includes a method for identifying novel phosphopeptide-binding domains. | 05-05-2011 |
| 20110129852 | ORGANIC COMPOUNDS - The present invention relates to isolated polypeptides which comprise an amino acid sequence consisting of a mutated functional Abl kinase domain, said mutated functional kinase domain being resistant to inhibition of its tyrosine kinase activity by N-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-4-(4-methyl-piperazin-1-ylmethyl)-benzamide or a salt thereof, to the use of such polypeptides to screen for compounds which inhibit the tyrosine kinase activity of such polypeptides, to nucleic acid molecules encoding such polypeptides, to recombinant vectors and host cells comprising such nucleic acid molecules and to the use of such nucleic acid molecules in the production of such polypeptides for use in screening for compounds which inhibit the tyrosine kinase activity of such polypeptides. | 06-02-2011 |
| 20110129853 | POLYSACCHARIDE-PROTEIN BINDING MODEL AND NANO-FIBRIL FORMATION OF A STARCH BINDING DOMAIN - A polysaccharide-protein binding model of SBD, and a fibril-forming 14-residue peptide consisting of X | 06-02-2011 |
| 20110143370 | Nucleic Acids Encoding a Mammalian Raptor Polypeptide and Uses Therefor - The present invention relates to isolated raptor nucleic acid molecules of mammalian origin (e.g., human) and complements, portions and variants thereof. Another aspect of the invention are isolated raptor polypeptides of mammalian origin and portions thereof, and antibodies or antigen binding fragments thereof that specifically bind a raptor polypeptide. The present invention also relates to constructs and host cells comprising the nucleic acid molecules described herein. In addition, the present invention relates to uses of the nucleic acid and polypeptide molecules provided herein. | 06-16-2011 |
| 20110143371 | PROCOLLAGEN C-PROTEINASE ENHANCER (PCPE) BIOMARKER FOR BONE FORMATION - Use of PCPE, preferably PCPE-1, as a diagnostic marker. | 06-16-2011 |
| 20110177526 | JANUS FAMILY KINASES AND IDENTIFICATION OF IMMUNE MODULATORS - An isolated polynucleotide encodes JAK-3 protein. JAK-3 protein is a protein tyrosine kinase having a molecular weight of approximately 125 kDa which has tandem non-identical catalytic domains, lacks SH2 or SH3 domains, and is expressed in NK cells and stimulated or transformed T cells, but not in resting T cells. The protein itself and antibodies to this protein are also presented. Further, methods of identifying therapeutic agents for modulating the immune system make use of the foregoing. | 07-21-2011 |
| 20110177527 | METHODS AND COMPOUNDS FOR TESTING BINDING OF A LIGAND TO A G PROTEIN-COUPLED RECEPTOR - The present invention relates to compounds and methods for testing for the binding of a ligand to a G Protein-Coupled Receptor. In particular, the compounds of the invention are useful in high throughput screening for ligands which bind to G Protein-Coupled Receptors. | 07-21-2011 |
| 20110183358 | METHODS AND COMPOSITIONS FOR DEREPRESSION OF IAP-INHIBITED CASPASE - The invention provides isolated agents having novel chemical structures and possessing superior activity as derepressors of IAP inhibited caspase. The invention further provides a method of derepressing an IAP-inhibited caspase. The invention further provides assay methods employing labeled compounds of the invention, especially fluorescent labeled compounds. | 07-28-2011 |
| 20110201025 | Polymer-coupled peptidases - The present invention is directed to a simple process for the modification of the specificity of a peptidase of the hemostatic system by coupling polymers to the peptidase causing it to lose its reactivity in the hemostatic system, but enabling it to continue to react with certain inhibitors, effectors and substrates. The invention is furthermore directed to processes for the detection or quantitative determination of inhibitors of the peptidase in bodily fluids or other samples as well as to processes for their neutralization and/or removal from liquids. Finally, the invention allows the use of a polymer-coupled peptidase as drug and furthermore provides a device which makes use of such a peptidase in the removal of peptidase inhibitors from samples or from the bloodstream of a patient. | 08-18-2011 |
| 20110212466 | Thiol-Modified Surface Immobilization Article And Method - A method and article to immobilize a protein, including, for example, combining the protein and a mixture comprised of an activated spacer compound having a maleimide group in a buffer solution, to form a maleimide-modified protein; and contacting the maleimide-linker-modified protein and a buffer swollen, thiol-modified, surface bound polymer to immobilize the maleimide-linker-modified protein on the polymer surface of the article. Also disclosed are articles having an immobilized protein thereon, and to methods of using the articles having an immobilized protein, as defined herein. | 09-01-2011 |
| 20110212467 | INHIBITORS OF dUTPase - Evidence demonstrating that elevated expression of dUTPase protects breast cancer cells from the expansion of the intracellular uracil pool, translating to reduced growth inhibition following treatment with 5-FU is provided. The implementation of in silica drug development techniques to identify and develop small molecule inhibitors of dUTPase are reported. As 5-FU and the oral 5-FU pro-drug capecitabine remain central agents in the treatment of a variety of malignancies, the clinical utility of a small molecule inhibitor to dUTPase represents a viable strategy to improve the clinical efficacy of these mainstay chemotherapeutic agents. | 09-01-2011 |
| 20110244480 | METHOD OF DIAGNOSIS AND KIT THEREFOR - The invention provides kits and methods for detecting or monitoring the number of cells in sample. The cell comprises a cell surface associated protein (CSAP) comprising a cytoplasmic (cytosolic) and an extracellular (ecto) domain. The kit comprises: (i) a chromatographic device; and (ii) a CSAP-binding agent. The method comprises: (i) optionally contacting the sample with an agent capable of lysing or permeabilizing CSAP bearing cells; (ii) contacting the sample with a CSAP-binding agent that binds to the cytoplasmic domain of the CSAP; and (iii) directly or indirectly evaluating the level or presence of bound CSAP in the sample. | 10-06-2011 |
| 20110244481 | COELENTERAZINE ANALOGUES AND COELENTERAMIDE ANALOGUES - Coelenterazine analogues with different luminescence properties from conventional ones and coelenteramide analogues with different fluorescence properties from conventional ones have been desired. The invention provides coelenterazine analogues modified at the 8-position of coelenterazine and coelenteramide analogues modified at the 2- or 3-position of coelenteramide. | 10-06-2011 |
| 20110256553 | Methods - A method for assessing the effect of a test compound on LRRK2 in a cell-based system, the method comprising the steps of a) assessing the effect of exposing the cell-based system comprising LRRK2 to the test compound on the phosphorylation state of Ser910 and/or Ser935 of the LRRK2; and/or b) assessing the effect of exposing the cell-based system comprising LRRK2 to the test compound on the binding of the LRRK2 to a 14-3-3 polypeptide. The method is considered to be useful in assessing the effect of putative LRRK2 inhibitors in cell based systems, including in vivo systems. | 10-20-2011 |
| 20110262936 | METHOD OF DETERMINING A CONCENTRATION OF ANALYTES OF INTEREST IN A SAMPLE - A method of determining a concentration of analytes of interest in a sample reaction mixture is disclosed. The method can include measuring intensities of the polarized fluorescence of at least one comparative reaction mixture containing different, known amounts of the analytes of interest, and measuring the intensities of the polarized fluorescence of a sample reaction mixture. The method can also include determining the preliminary concentrations of the analytes of interest in the sample reaction mixture by comparing the measured intensities of the sample reaction mixtures at various time points. The margin of error for the preliminary concentration of the analytes of interest in the sample can be determined at the various time points. Finally, the concentration of the analytes of interest in the sample reaction mixture can be determined by comparing the preliminary concentrations and the respective margin of error at the given time points. | 10-27-2011 |
| 20120003668 | HIGH RESOLUTION COMPLEX STRUCTURE AND ALLOSTERIC EFFECTS OF LOW MOLECULAR WEIGHT ACTIVATORS ON THE PROTEIN KINASE PDK1 - The present invention provides a mutant form of a protein kinase its production and its use for identifying compounds that bind to the PIF-binding pocket allosteric site of the protein kinase. | 01-05-2012 |
| 20120021436 | Crystal structure of human alpha-N-acetylglucosaminidase - The present invention provides the three-dimensional structure of human α-N-acetylglucosaminidase (NAGLU) protein. This crystallographic information is useful in the identification and development of novel binding compounds of NAGLU, NAGLU mutants, for example, those associated with Sanfilippo syndrome type B (mucopolysaccharidosis III B (MPS III-B)), and other NAGLU family members (family 89 α-N-acetylglucosaminidase) which may modulate the activity and/or stability of mutated NAGLU. Such compounds may be useful for the treatment of Sanfilippo syndrome type B (mucopolysaccharidosis III B (MPS III-B)). | 01-26-2012 |
| 20120149032 | ENZYME DETECTION DEVICE - An enzyme detection device ( | 06-14-2012 |
| 20120183974 | NOVEL GENES RELATED TO GLUTAMINYL CYCLASE - Novel glutaminyl-peptide cyclotransferase-like proteins (QPCTLs), which are isoenzymes of glutaminyl cyclase (QC, EC 2.3.2.5), and to isolated nucleic acids coding for these isoenzymes, all of which are useful for the discovery of new therapeutic agents, for measuring cyclase activity, and for determining the inhibitory activity of compounds against these glutaminyl cyclase isoenzymes. | 07-19-2012 |
| 20120190045 | Peptide Inhibitors of ABL Kinases - Provided are purified compounds comprising SEQ ID NO:1, where the tyrosine at residue ( | 07-26-2012 |
| 20120214173 | Methods of Identifying Modulators of an Ehd Polypeptide - The invention relates to a method of identifying a modulator of an EHD family polypeptide, said method comprising (i) providing a first and second sample of an EHD polypeptide; (ii) contacting said first sample with a candidate modulator; (iii) contacting said first and second samples with ATP; and (iv) monitoring ATP hydrolysis in said first and second samples, wherein a difference between the ATP hydrolysis in said first and second samples identifies said candidate modulator as a modulator of an EHD family polypeptide. The invention also relates to methods of modelling molecules and to various EHD mutant polypeptides. | 08-23-2012 |
| 20120219964 | BACTERIAL ATP SYNTHASE BINDING DOMAIN - This invention provides an isolated mutant atpE protein and departing from said mutant atpE protein the identification of an ATPase binding domain. This invention also provides related nucleic acids, vectors, host cells, pharmaceutical compositions and articles of manufacture. This invention further provides methods for determining whether a test compound interacts with an atpE protein, i.e. with the ATPase binding domain of the present invention, as well as pharmaceuticals compositions comprising said test compound, in particular as antimicrobials, more particular as antimycobacterial agent, even more particular for treating tuberculosis in a subject. | 08-30-2012 |
| 20120219965 | MASP 2, A COMPLEMENT-FIXING ENZYME, AND USES FOR IT - The invention relates to the discovery and characterization of mannan binding lectin-associated serine protease-2 (MASP-2), a new serine protease that acts in the MBLectin complement fixation pathway. | 08-30-2012 |
| 20120225437 | METHODS FOR IDENTIFYING INHIBITORS OF MANNAN-BINDING LECTIN ASSOCIATED SERINE PROTEASE (MASP) PROTEINS AND USES THEREOF - This disclosure is directed to methods and compositions to inhibit MASP protein activity using small molecule inhibitors. In one aspect, the disclosure is directed to methods for identifying inhibitors of MASP protein activity, including methods of screening capable of inhibiting MASP protein activity. | 09-06-2012 |
| 20120237949 | SPECIFIC DETECTION AND QUANTIFICATION OF PHOSPHATIDIC ACID USING AN ARABIDOPSIS TRIGALACTOSYLDIACYLGLYCEROL-4 (TGD4) PROTEIN - The present invention is related to the field of phospholipid detection. In particular, certain embodiments provide the detection of phosphatidic acid. For example, certain proteins are capable of binding phosphatidic acid and can be used as a diagnostic and/or research tool to identify and quantitate phosphatidic acid. Phosphatidic acid may be in or from cells and tissues isolated from plants, animals and humans. For example, a trigalactosyldiacylglycerol-2 (TGD2) protein may be fused with a fluorescent probe to monitor and measure phosphatidic acid in vitro as well as in vivo. In other embodiments, a trigalactosyldiacylglycerol-4 (TGD4) protein may be fused with a fluorescent probe to monitor and measure phosphatidic acid in vitro as well as in vivo. In additional embodiments, a fragment comprising either a truncated TGD2 or TGD4 phosphatidic acid binding region protein may be used to monitor or measure phosphatidic acid. | 09-20-2012 |
| 20120258471 | PEPTIDE MARKER FOR CANCER DIAGNOSIS, AND CANCER DIAGNOSIS METHOD USING SAME - The present invention relates to a peptide marker for cancer diagnosis and a cancer diagnosis method using the same, more precisely to a peptide marker for cancer diagnosis screened by the following steps: separating and concentrating glycoproteins including a certain glycan chain related to the occurrence of cancer; hydrolyzing the glycoproteins to obtain polypeptides; and quantitatively analyzing the polypeptides to identify certain polypeptides that can track quantitative changes in glycoproteins glycosylated in a specific manner by the occurrence of cancer, and to a cancer diagnosis method using the said peptide marker. | 10-11-2012 |
| 20120282628 | METHOD FOR DIAGNOSING CANCER USING LECTIN - The present invention relates to a method for diagnosing cancer using information on aberrant glycosylation of glycoproteins, which is related with cancer progression. More particularly, the present invention relates to a peptide marker for cancer diagnosis and a method for diagnosing cancer using the peptide marker, wherein glycoproteins aberrantly glycosylated due to cancer incidence and progression is isolated using lectin; and marker peptides generated by hydrolysis of the glycoproteins isolated by the lectin is selected and quantified. | 11-08-2012 |
| 20120288875 | Diagnostic Test For The Detection Of A Molecule Or Drug In Whole Blood - The invention provides methods of preparing a test sample for use in an assay for detecting an analyte bound by an intracellular ligand. The methods typically involve contacting the test sample with an assay reagent comprising: a lysis reagent; and a protease that has proteolytic activity for said intracellular ligand; to form a mixture compatible for use in an immunoassay without subsequent extraction steps. Other aspects of the invention include related immunoassays and test kits. | 11-15-2012 |
| 20120295283 | FLUORESCENT MOLECULAR PROBES FOR USE IN ASSAYS THAT MEASURE TEST COMPOUND COMPETITIVE BINDING WITH SAM-UTILIZING PROTEINS - Assay methods may generally comprise forming homogeneous assay mixtures comprising target SAM-utilizing protein, fluorescent detection analyte, and test compound, incubating, and measuring FP or TR-FRET signal emitted in order to determine a measure of test compound-SAM-utilizing protein binding. Assay mixtures comprise a SAM-utilizing protein, and a fluorescent detection analyte that binds with the SAM-utilizing protein in the absence of test compound. Assay mixtures may further comprise a test compound. Assay mixture embodiments may generate FP or TR-FRET signal properties that are a function of the inherent binding interactions of both the test compound and the detection analyte with the SAM-utilizing protein. Fluorescent detection analytes comprise a fluorophore moiety, a covalent linker moiety, and a SAM-utilizing protein ligand moiety and could be utilized in FP or TR-FRET assays to measure test compound binding. | 11-22-2012 |
| 20120301895 | METHODS OF MODULATING BINDING OF SON OF SEVENLESS TO PHOSPHATIDIC ACID AND IDENTIFYING COMPOUNDS THAT MODULATE SUCH BINDING - The present invention relates to methods of modulating binding of Son of sevenless to phosphatidic acid and identifying compounds that modulate such binding. In particular, the present invention relates to a method of controlling pleckstrin homology domain-dependent membrane recruitment of Son of sevenless or histone folds domain-dependent membrane recruitment of Son of sevenless. Also disclosed are methods of controlling Ras and treating a subject for a condition mediated by Ras. The present invention also relates to a method of identifying compounds potentially effective in treating a condition mediated by Ras. | 11-29-2012 |
| 20120309022 | METHOD OF DETERMINATION OF RENAL CELL CARCINOMA - The present invention provides a novel method for diagnosing renal cell carcinoma. The method of the invention allows evaluation of the presence of renal cell carcinoma or the degree of malignancy of renal cell carcinoma, by conducting comprehensive analysis of N-linked sugar chains in serum of a patient and utilizing an expression level of detected sugar chain as an index of the evaluation. | 12-06-2012 |
| 20120309023 | DUAL ACTIVITY KINASE DOMAINS AND USES THEREOF - The present invention relates to a dual activity domain JAK proteins, namely JH2. It is provided that the JH2 domain is a true and important target for drug development, especially for diseases caused by aberrant JAK signalling, such as myeloproliferative disorders and leukemias. | 12-06-2012 |
| 20120322082 | BIOMARKER FOR AMYOTROPHIC LATERAL SCLEROSIS AND DIAGNOSTIC KIT AND METHOD USED THEREOF - A diagnostic marker for determining of a patient with amyotrophic lateral sclerosis (ALS), comprising an autoantibody against a human protein HMGB1 is described. A diagnostic kit for determining of a patient with ALS, comprising: (a) an HMGB1 protein; and (b) an HMGB1 antibody standard is also presented. A method of determining ALS in a subject, comprising the steps: (a) detecting autoantibody against HMGB1 in a biological sample taken from the subject and normal control individuals; and (b) statistically comparing concentrations of the autoantibody against HMGB1 in the subject with that of the normal control individuals obtained from step (a); wherein a higher concentration of the autoantibody against HMGB1 in the subject than a cut-off concentration indicates the subject suffers from ALS is further described. | 12-20-2012 |
| 20130004966 | STRUCTURE OF CYTOKININS AND CYTOKININ RECEPTORS, AND MODULATION OF CYTOKININ SIGNALING - Provided herein are seven high resolution crystal structures showing the cytokinin receptor AHK4 complexed with various naturally occurring and synthetic ligands. Further provided are strategies for modulating cytokinin receptor activity. | 01-03-2013 |
| 20130004967 | MICROWELL ARRAY ARTICLES AND METHODS OF USE - The disclosure provides microstructured articles and methods useful for detecting an analyte in a sample. The articles include microwell arrays. The articles can be used with an optical system component in methods to detect or characterize an analyte | 01-03-2013 |
| 20130040313 | Nanofluidic biochemical sensors based on surface charge modulated ion current - Biological and chemical sensors based on surface charge changes in a pore or channel, such as a nanopore or nanochannel, are employed to detect targeted analytes in an electrolyte solution having a low ion concentration. Receptors within the pore or channel capture a targeted analyte, causing a change in surface charge that affects ionic conductance. The change in ionic conductance is detected, evidencing the presence of the targeted analyte. A secondary tag may be introduced to the pore or channel for binding with a captured analyte in certain circumstances for causing a change in the surface charge. | 02-14-2013 |
| 20130052660 | METHOD FOR DETECTING PROTEIN-PROTEIN INTERACTIONS IN CELLS - The present invention relates to a method for detecting protein-protein interactions in living cells, and more particularly, to a method for providing cells comprising a first construct and a second construct, wherein the first construct comprises a polynucleotide encoding a first fusion protein which comprises a bait protein, a first fluorescent protein and a CBD (cellulose-binding domain) protein, and wherein the second construct comprises a polynucleotide encoding a second fusion protein which comprises a prey protein and a second fluorescent protein so as to allow formation of inclusion bodies, and detecting interactions between the bait protein and the prey protein that are displayed by inclusion bodies, a method for isolating the prey protein bound to the bait protein using the cells comprising the constructs, the cells, and a kit for detecting protein-protein interactions, comprising the constructs. | 02-28-2013 |
| 20130065250 | Kit and Method for Detecting Porous Dental Hydroxyapatite - The present invention relates to a kit and a probe for detecting porous dental hydroxyapatite, comprising a protein capable of binding porous dental hydroxyapatite or a detector thereof. The invention also relates to a method for detecting a condition involving porous dental hydroxyapatite comprising detecting in or on a tooth or a sample of the tooth of a subject a protein bound to porous dental hydroxyapatite. The invention also relates to methods for detecting a hypomineralisation developmental dental defect or detecting intact and/or broken MIH enamel, and to a kit and method for removing a protein bound to porous dental hydroxyapatite. | 03-14-2013 |
| 20130065251 | METHOD AND SYSTEM FOR DETERMINATION OF MOLECULAR INTERACTION PARAMETERS - A method of determining kinetic parameters for a reversible molecular interaction between a ligand immobilized to a solid support surface and a binding partner to the ligand in solution, comprises sequentially, without intermediate regeneration or renewal of the immobilized ligand, flowing a plurality of fluid volumes containing different known concentrations of the binding partner over the solid support surface, monitoring the momentary amount of binding partner bound to the solid support surface related to time and solution concentration of binding partner and collecting the binding data, and determining the kinetic parameters by globally fitting a predetermined kinetic model for the interaction between the binding partner and the immobilized ligand to the collected binding data, which model allows for mass transport limitation at the solid support surface. An analytical system for carrying out the method, a computer program, a computer program product and a computer system for performing the method are also disclosed. | 03-14-2013 |
| 20130071856 | METHOD AND BIOMARKER FOR EVALUATING METASTASIS, AND SIRNA COMPOUND FOR INHIBITING METASTASIS - A method and biomarker for evaluating metastasis, and an siRNA compound for inhibiting metastasis. The method of the present invention includes: providing a sample of a subject, which includes a normal tissue and a tissue to be detected; detecting expression of a biomarker of the normal tissue and the tissue to be detected, respectively, wherein the biological marker is SERPINA1; and comparing the expression of the biological marker of the normal tissue and the tissue to be detected. When the expression of the biological marker of the tissue to be detected is higher than the normal tissue, it represents that the subject is at a risk of suffering from metastasis. | 03-21-2013 |
| 20130084583 | VARIANTS OF VEGFR AND THEIR USE IN THE DIAGNOSIS AND TREATMENT OF PREGNANCY ASSOCIATED MEDICAL CONDITIONS - An isolated polypeptide comprising an amino acid sequence at least 70% homologous to SEQ ID NO: 4 and an isolated polynucleotide encoding same are disclosed. A polynucleotide comprising a nucleic acid sequence capable of specifically hybridizing to the isolated polynucleotide and an isolated antibody comprising an antigen recognition domain which specifically binds the isolated polypeptide are also disclosed. Pharmaceutical compositions, methods of diagnosing and treating comprising same are also disclosed. | 04-04-2013 |
| 20130109031 | INHIBITOR SCAFFOLD FOR THE INHIBITION OF THE ENZYME PHOSPHOENOLPYRUVATE CARBOXYKINASE | 05-02-2013 |
| 20130273564 | DISPERSION INJECTION METHODS FOR BIOSENSING - I Injection methods for determining biomolecular interaction parameters such in label-free biosensing systems are provided. The methods generally relate to analyte sample injection methods that generate well-defined analyte concentration gradients en route to a sensing region possessing an immobilized binding partner. The injections conditions are generally established according to a set of rules that create a dispersion event that can be accurately modeled by a dispersion term. The dispersion term is incorporated into the desired interaction model to provide a reliable representation of the analyte concentration gradient profile, The resulting interaction model is then fitted to a measured binding response curve in order to calculate the interaction parameters. Thus, the injection methods described herein provide a continuous analyte titration allowing a full analyte dose response to be recorded in a single injection in contrast to the standard multiple injection approach | 10-17-2013 |
| 20130288271 | METHODS FOR DETECTING ALLOSTERIC MODULATORS OF PROTEIN - The present invention discloses, inter alia, methods for labeling a target protein with an SHG-active probe for detection by second harmonic or sum-frequency generation in order to identify agents which bind to an allosteric site on the target protein thereby altering its structural conformation | 10-31-2013 |
| 20140004532 | Nucleic Acids Encoding a Mammalian Raptor Polypeptide and Uses Therefor | 01-02-2014 |
| 20140038205 | METHODS AND COMPOSITIONS RELATING TO COAGULATION ASSAYS - The invention provides methods and compositions relating to the detection and neutralization of heparin and heparin derivatives in vivo and in vitro. To neutralize heparin in a patient sample, a composition comprising a complex of a heparin-binding agent and a carrier compound is used prior to performing coagulation assays. | 02-06-2014 |
| 20140045193 | METHIONINE METABOLITES PREDICT AGGRESSIVE CANCER PROGRESSION - The invention relates to the use of enzymes and nanorods to detect cysteine level in a patient sample and relates to the use of the detected cysteine level to predict cancer recurrence in the patient. The invention is directed to systems and methods of detecting cysteine level in a sample from a subject, wherein the systems or methods can further comprise measuring at least one additional parameter, such as PSA level, Gleason score and clinical stage. The invention is directed to systems and methods of predicting the probability of a recurrence of a cancer in a subject, wherein the systems or methods can further comprise measuring at least one additional parameter, such as PSA level, Gleason score and clinical stage. This invention is directed to systems and methods of predicting the probability of a recurrence of a cancer in a subject and treating the subject, wherein the systems or methods can further comprise measuring at least one additional parameter, such as PSA level, Gleason score and clinical stage. | 02-13-2014 |
| 20140051095 | ENZYME DETECTION DEVICE - An enzyme detection device ( | 02-20-2014 |
| 20140113312 | CLASSIFICATION OF KINASE INHIBITORS USING NONLINEAR OPTICAL TECHNIQUES - A method is disclosed for classifying and distinguishing between type I and type II kinase inhibitors. The method involves the use of non-linear optical techniques, in particular second-harmonic generation (SHG) to identify conformational changes in kinase proteins obtained from known type I or type II inhibitors. The method further involves deducing the manner of binding of unknown inhibitors by comparison with the signal changes produced by known ligands. The method is also applied to comparing the conformational changes induced by the binding of generic and branded kinase inhibitor drugs to a target kinase. | 04-24-2014 |
| 20140134641 | MASP-2, A COMPLEMENT FIXING ENZYME, AND USES FOR IT - The invention relates to the discovery and characterization of mannan binding lectin-associated serine protease-2 (MASP-2), a new serine protease that acts in the MBLectin complement fixation pathway. | 05-15-2014 |
| 20140134642 | Characterization of biochips containing self-assembled monolayers - The present invention relates to a method of characterizing biochips with matrix-assisted laser desorption/ionization and time of flight mass spectrometry (MALDI-TOF MS). | 05-15-2014 |
| 20140162287 | Method for Prognosing Response to Cancer Therapy with 5, 10, 15, 20-Tetrakis (Carboxyphenyl) Porphine - Presented is a method of prognosing a patient's response to a cancer therapy wherein prior to the therapy contacting a sample of cells from the patient's tissue or organ being treated for the cancer with a solution of TCPP to permit binding of the TCPP to components of the abnormal dysplastic or carcinomic cells, if any are present; detecting TCPP fluorescence in the sample, the presence of TCPP fluorescence being indicative that the sample contains dysplastic or carcinomic cells; at intervals during the therapy and subsequent to the therapy performing steps a-c on another sample of cells from the patient's tissue or organ being treated for the cancer; and determining if the percentage of abnormal pre-cancerous cells in the samples tested during and subsequent to the therapy are reduced as compared with the sample tested prior to the therapy, the reduction being prognostic of the patients response to the cancer therapy. | 06-12-2014 |
| 20140162288 | BIOMARKER FOR REPLICATIVE SENESCENCE - The present invention provides biomarkers for replicative senescence. In particular, Lamin B1 is provided as a biomarker for replicative senescence. | 06-12-2014 |
| 20140220595 | COMPETITION-BASED DETECTION ASSAYS - Disclosed herein are methods and kits which are useful for detecting presence of an enzyme and the relative amount of glycan associated with the enzyme in a test sample based upon the enzyme's ability to competitively inhibit the binding of a ligand in such test sample. The present invention provides the ability to evaluate cell culture conditions and optimize the desired glycoform content of recombinantly prepared enzymes. | 08-07-2014 |
| 20140220596 | METHOD FOR SCREENING AN AGENT PREVENTING OR TREATING CANCER USING GLYCYL-TRNA SYNTHETASE AND CADHERIN - The present invention relates to a novel method of screening an agent for preventing or treating cancer using glycyl-tRNA synthetase (GRS) and cadherin (CDH). More particularly, it relates to a method of screening and test agent which modulates the binding level of GRS or their fragment with CDH. As can be seen foregoing, the present invention relates to a novel use of GRS and CDH and provides a method of screening an agent for preventing or treating cancer. The method may be used for developing novel agent for treatment of various cancer. | 08-07-2014 |
| 20140234862 | COMPOSITIONS AND METHODS FOR QUANTITATIVELY MONITORING LIPIDS - Provided herein are fluorescent lipid binding proteins (FLBPs). The FLBPs comprise a lipid binding domain linked to a fluorophore, whereby the fluorophore's fluorescence emission undergoes a spectral change upon lipid binding. | 08-21-2014 |
| 20140273011 | DETECTION METHODS OF NADP(H) USING MBFP - Provided is a detection method of NADP(H) from the change of a fluorescence intensity by a reaction between metagenome-derived blue fluorescent protein (mBFP) and NADPH. More particularly, the present invention relates to methods for detecting NADP(H) using mBFP or his-mBFP, or methods for detecting NADP(H) for measuring an activity of NADP(H) dependent dehydrogenase or oxidoreductase. | 09-18-2014 |
| 20140308681 | SENSORS EMPLOYING SINGLE-WALLED CARBON NANOTUBES - Sensing compositions, sensing element, sensing systems and sensing devices for the detection and/or quantitation of one or more analytes. Compositions comprising carbon nanotubes in which the carbon nanotubes retain their ability to luminesce and in which that luminescence is rendered selectively sensitive to the presence of an analyte. Compositions comprising individually dispersed carbon nanotubes, which are electronically isolated from other carbon nanotubes, yet which are associated with chemical selective species, such as polymers, particularly biological polymers, for example proteins, which can interact selectively with, or more specifically selectivity bind to, an analyte of interest. Chemically selective species bind, preferably non-covalently, to the carbon nanotube and function to provide for analyte selectivity. Chemically selective species include polymers to which one or more chemically selective groups are covalently attached. Chemically selective polymers include, for example, proteins and polysaccharides. | 10-16-2014 |
| 20140308682 | GRAPHENE-BIOMOLECULE BIOELECTRONIC DEVICES - Provided are devices and methods featuring a nanoelectronic interface between graphene devices (for example, field effect transistors or FETs) and biomolecules such as proteins, which in turn provides a pathway for production of bioelectronic devices that combine functionalities of the biomolecular and inorganic components. In one exemplary application, one may functionalize graphene FETs with fluorescent proteins to yield hybrids that respond to light at wavelengths defined by the optical absorption spectrum of the protein. The devices may also include graphene in electronic communication with a biomolecule that preferentially binds to a particular analyte. | 10-16-2014 |
| 20140322727 | ASSAY - The present invention discloses an assay device ( | 10-30-2014 |
| 20140335539 | METHOD FOR DETECTING PROTEIN-PROTEIN INTERACTION - A method for detecting an interaction between a first protein and a second protein comprises the steps of:
| 11-13-2014 |
| 20140377775 | METHOD FOR DETECTING AND REMOVING ENDOTOXIN - The present invention relates to bacteriophage tail proteins and the derivatives and fragments thereof that are capable of binding endotoxins in the absence of bivalent positive ions, especially Ca | 12-25-2014 |
| 20140377776 | METHODS FOR DETECTING ALLOSTERIC MODULATORS OF PROTEIN - The present invention discloses, inter alia, methods for labeling a target protein with an SHG-active probe for detection by second harmonic or sum-frequency generation in order to identify agents which bind to an allosteric site on the target protein thereby altering its structural conformation | 12-25-2014 |
| 20150010921 | Cell Death Assay - The present invention relates to a method for detecting cell death using a luminescent compound; to the luminescent compounds for particular uses; to a kit comprising compounds and to a protein. The method is applicable for detecting cell death, essentially regardless of the mechanism through which cell death occurred or is occurring and is therefore not limited e.g. to detecting cell death resulting from only one mechanism selected from apoptosis and necrosis. | 01-08-2015 |
| 20150017657 | ASSAY AND METHOD FOR IDENTIFYING COMPOUNDS THAT INHIBIT EXCITOTOXIC SIGNALS - The invention relates to an assay for identifying compounds for the treatment of various diseases including those associated with excitotoxicity. The invention also relates to cell lines and constructs for use in an assay of the invention. The invention also relates to methods for determining whether a compound reduces excitotoxic signalling in a cell and whether a compound that inhibits binding of Tau to Fyn is likely to selectively reduce excitotoxic cell signalling. The invention also relates to a Tau protein adapted to form a detectable signal when the Tau protein is bound to a Fyn protein. The invention also relates to a Fyn protein adapted to form a detectable signal when the Fyn protein is bound to a Tau protein. | 01-15-2015 |
| 20150031050 | Method of Screening Therapeutic Agent for Treating Inflammatory Diseases - Uses and applications derived from the discovery of a novel binding site of IKK-β, such as method of screening a therapeutic agent as drug candidate for treating cancer, inflammation, or other diseases/disorders, are provided. | 01-29-2015 |
| 20150037817 | BIFUNCTIONAL TUMOR DIAGNOSIS REAGENT AND METHOD FOR TUMOR DIAGNOSIS - The invention relates to a bifunctional tumor diagnostic reagent and a method for tumor diagnosis. The reagent consists of a protein shell specifically recognizing a cancer tissue and/or a cancer cell and an inorganic nano-core having the catalytic activity of a peroxidase. The bifunctional tumor diagnostic reagent has two functions, i.e., tumor specific identification and color development, and enables the tumor specific identification and the color development to be completed in one step, and the operation of the process is simple and convenient. | 02-05-2015 |
| 20150044692 | DEVELOPMENT AND USE OF FLUORESCENT PROBES OF UNBOUND BILIRUBIN - Identification and use of proteins fluorescently labeled and that undergo a change in fluorescence index upon binding bilirubin are described. Probes are disclosed which are labeled at a cysteine or lysine residue and also probes labeled at both cysteine and lysine with two different fluorophores. These probes are useful for determination of unbound bilirubin levels in a fluid sample. | 02-12-2015 |
| 20150079608 | METHOD FOR DETECTING OR QUANTIFYING ANALYTE, KIT FOR DETECTING OR QUANTIFYING ANALYTE, AND TEST STRIP FOR LATERAL FLOW TYPE CHROMATOGRAPHY METHOD FOR DETECTING OR QUANTIFYING ANALYTE - A method for detecting or quantifying an analyte, using a test strip for lateral flow type chromatography which contains a membrane and a detection part on which a capturing ligand that is to specifically bind to the analyte has been fixed on the membrane, includes: bringing an analyte contained in a sample into contact with a labeled ligand labeled with a phosphor that is to be excited by light having a wavelength from 600 nm to 800 nm to generate fluorescence, bringing a complex containing the analyte and the labeled ligand into contact with a capturing ligand at the detection part, and irradiating on the test strip light having a wavelength from 600 nm to 800 nm as an excitation light for the phosphor contained in the complex to generate fluorescence from the phosphor, and measuring a fluorescence intensity of the fluorescence. | 03-19-2015 |
| 20150093760 | CARTRIDGE AND SYSTEM FOR DETECTING OF GLYCATED PROTEIN IN SAMPLE AND METHOD OF DETECTING GLYCATED PROTEIN USING THE SAME - A cartridge for measuring a concentration of a glycated protein in a wide measurement range, a system for measuring a glycated protein, and a method of measuring a glycated protein using same. | 04-02-2015 |
| 20150104808 | Cysteine Engineered Fibronectin Type III Domain Binding Molecules - Cysteine engineered monospecific and bispecific EGFR and/or c-Met FN3 domain containing molecules comprising one or more free cysteine amino acids are prepared by mutagenizing a nucleic acid sequence of a parent molecule and replacing one or more amino acid residues by cysteine to encode the cysteine engineered FN3 domain containing monospecific or bispecific molecules; expressing the cysteine engineered FN3 domain containing molecules; and recovering the cysteine engineered FN3 domain containing molecule. Isolated cysteine engineered monospecific or bispecific FN3 domain containing molecules may be covalently attached to a detection label or a drug moiety and used therapeutically. | 04-16-2015 |
| 20150125877 | Weak Affinity Chromatography - The present invention provides methods for analyzing a target compound from a biological sample. In one aspect, a method for analyzing a target compound in a biological sample can comprise delivering a biological sample through an affinity column, the affinity column having a binding ligand coupled to a stationary structural support, wherein the affinity column has a high density of the binding ligand per the stationary structural support and wherein the binding ligand has been preselected to cause weak affinity separation zonal retardation of the target compound from the biological sample forming a target compound fraction and a biological sample fraction and detecting the target compound by mass spectrometry. | 05-07-2015 |
| 20150140574 | METHOD FOR PRODUCING HORSERADISH PEROXIDASE RECOMBINANT PROTEIN USING FILAMENTOUS FUNGUS - A modified polynucleotide has a different base sequence in at least one codon from a wild-type base sequence encoding a horseradish peroxidase polypeptide. The usage frequency of the modified codon of the polynucleotide corresponds to the codon usage frequencies of three filamentous fungal species in | 05-21-2015 |
| 20150140575 | METHODS FOR DETERMINING LIGAND BINDING TO A TARGET PROTEIN USING A THERMAL SHIFT ASSAY - The invention is directed to a method of determining whether a non-purified sample contains a target protein bound to a ligand of interest comprising the steps of: a) exposing said non-purified sample to a temperature which is capable of causing or enhancing precipitation of the unbound target protein to a greater extent than it is capable of causing or enhancing precipitation of the target protein bound to said ligand; b) processing the product of step a) in order to separate soluble from insoluble protein; and c) analysing either or both the soluble and insoluble protein fractions of step b) for the presence of target protein, wherein said target protein is not detected on the basis of enzymatic activity of a tag, peptide, polypeptide or protein fused thereto. Particularly, the invention may be used to determine whether drugs can bind to their protein targets in samples derived from patients to ascertain whether a certain drug can be used in a therapy for that patient. Additionally, the invention is directed to an instrument for use in the methods of the invention and use of a kit in the methods of the invention comprising an antibody and/or a non-protein fusion tag. | 05-21-2015 |
| 20150291668 | ABD BINDING POLYPEPTIDE - The disclosure provides an ABD binding polypeptide comprising an ABD binding motif BM, which motif consists of an amino acid sequence selected from EX | 10-15-2015 |
| 20150293126 | Method for Diagnosing a Hemoglobin-Related Disorder - The invention relates to a method for diagnosing, staging and/or monitoring a hemoglobin-related disorder such as β-thalassemia or a treatment against said hemoglobin-related disorder in a subject in need thereof based on the detection and/or quantification the presence of free α-Hb pool in a biological sample obtained from said subject. | 10-15-2015 |
| 20150299684 | METHOD FOR RECOMBINANT PRODUCTION OF HORSESHOE CRAB FACTOR C PROTEIN IN PROTOZOA - The present invention provides a novel method for the recombinant production of Factor C protein from horseshoe crab using a parasitic protozoan expressing the Factor C protein. In particular, the present invention provides a parasitic protozoan host cell harbouring a polynucleotide encoding horseshoe crab Factor C protein, and a method for producing Factor C protein comprising culturing said parasitic protozoan host cell under conditions such that the cells express the horseshoe crab Factor C protein. Furthermore, the present invention provides recombinant Factor C protein produced by the novel method and its use in the detection and/or removal of endotoxin. | 10-22-2015 |
| 20150323542 | FLUORESCENT MOLECULAR PROBES FOR USE IN ASSAYS THAT MEASURE TEST COMPOUND COMPETITIVE BINDING WITH SAM-UTILIZING PROTEINS - Assay methods may generally comprise forming homogeneous assay mixtures comprising target SAM-utilizing protein, fluorescent detection analyte, and test compound, incubating, and measuring FP or TR-FRET signal emitted in order to determine a measure of test compound-SAM-utilizing protein binding. Assay mixtures comprise a SAM-utilizing protein, and a fluorescent detection analyte that binds with the SAM-utilizing protein in the absence of test compound. Assay mixtures may further comprise a test compound. Assay mixture embodiments may generate FP or TR-FRET signal properties that are a function of the inherent binding interactions of both the test compound and the detection analyte with the SAM-utilizing protein. Fluorescent detection analytes comprise a fluorophore moiety, a covalent linker moiety, and a SAM-utilizing protein ligand moiety and could be utilized in FP or TR-FRET assays to measure test compound binding. | 11-12-2015 |
| 20150369805 | ANALYTE SENSORS, METHODS FOR PREPARING AND USING SUCH SENSORS, AND METHODS OF DETECTING ANALYTE ACTIVITY - Analyte sensors, methods for producing and using analyte sensors, methods of detecting and/or measuring analyte activity, detecting pH change, and/or, controlling the concentration of an analyte in a system, are disclosed. Embodiments of the analyte sensors according to the disclosure can provide an accurate and convenient method for characterizing analyte activity, detecting pH change, controlling the concentration of an analyte in a system, and the like, in both in vivo and in vitro environments, in particular in living cell imaging. | 12-24-2015 |
| 20150369812 | FLAVONOID COMPOUNDS OF LOW TOXICITY FOR BIOLOGICAL IMAGING APPLICATIONS - Flavonoid compounds that are selective for a protein, a portion or a living cell, or a portion of an organism may be used as biological imaging agents. The flavonoid compounds are useful for methods of imaging organisms such as zebrafish embryos and zebra fish. Flavonoid compounds may also be used to detect protein. Advantageously, flavonoids that selectively bind protein, a portion of a living cell, or a portion of an organism may exhibit a florescence “turn-on” mechanism, where the flavonoids that are selectively bound exhibit a florescence response when excited. | 12-24-2015 |
| 20160033502 | COMPOSITIONS AND METHODS FOR DETECTION OF PROTEIN S-NITROSYLATION AND OXIDATION - The present invention discloses a novel isolated antibody that specifically binds to an N-phenyl-acetamide group. Also disclosed are related compositions, kits, methods for detecting protein S-nitrosylation or oxidation vivo or in vitro, and drug screening methods. | 02-04-2016 |
| 20160139162 | Inhibitors Of Fatty Acid Amide Hydrolase And Monoacylglycerol Lipase For Modulation Of Cannabinoid Receptors - Disclosed are compounds and compositions that inhibit the action of fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MGL), methods of inhibiting FAAH and MGL, methods of modulating cannabinoid receptors, and methods of treating various disorders related to modulation of cannabinoid receptors. | 05-19-2016 |
| 20160146794 | MEANS AND METHODS FOR BIOLUMINESCENCE RESONANCE ENERGY TRANSFER (BRET) ANALYSIS IN A BIOLOGICAL SAMPLE - The invention relates to the field of in vitro detection methods using luminescence. Provided is a sensor molecule for detecting an analyte of interest in a sample using bioluminescence resonance energy transfer (BRET), the sensor molecule comprising a proteinaceous moiety tethered to a synthetic regulatory molecule. Also provided is an analytical device comprising a sensor and methods using the sensor molecule. | 05-26-2016 |
| 20160178622 | Aptamer-Based Biosensing | 06-23-2016 |
| 20160251645 | MUTANT POLYPEPTIDES AND USES THEREOF | 09-01-2016 |
| 20160252522 | METHOD FOR PREPARING PEPTIDE FRAGMENTS, KIT FOR PREPARING PEPTIDE FRAGMENTS TO BE USED THEREIN, AND ANALYSIS METHOD | 09-01-2016 |
| 20160377605 | LYSOSOMAL ATP SELECTIVE TWO-PHOTON ABSORBING FLUORESCENT PROBE - A fluorescent probe compound, a preparation method thereof, and a method of imaging and quantifying lysosomal adenosine triphosphate (ATP) at a cell or tissue level through one-photon or two-photon fluorescence microscopy using the compound is disclosed. A fluorescence detection system capable of detecting lysosomal ATP is further disclosed. Since the fluorescent probe compound is found to be capable of selectively sensing and quantifying lysosomal ATP in a cell or tissue, it is expected that the disclosed compound or composition can be usefully employed in the study of various biological reactions or diseases associated with ATP in a living body. | 12-29-2016 |
